A Phase 2 interventional study of Cariprazine 3 mg and Cariprazine 6 mg in Schizophrenia, sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Tanabe Pharma Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.
Among the 23 studies testing cariprazine in Schizophrenia, this one is the 19th largest by enrollment, is one of 2 that started in 2008, is one of 4 in phase 2, and was the 4th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Gedeon Richter Plc. · Sites in United States, Bulgaria, Colombia and 5 more countries
Ages 13–17
New York State Psychiatric Institute
Ages 18–55
Bostal Drug Delivery Co., Ltd
Ages 18–65
By country, each count listing its studies:
cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 14
First in 2006; this study’s year is marked. 2 started in 2008.
This study's enrollment of 34 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 129 across the 23 interventional studies. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 23 have an industry lead sponsor. The 10 most frequent:
Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Tanabe Pharma Corporation has 6 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
3 of the studies testing cariprazine in Schizophrenia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cariprazine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fixed dose (low, medium or high) for 14 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cariprazine 3 mg
Drug: Cariprazine 6 mg
Drug: Cariprazine 12.5 mg
Also known as: Cariprazine(INN), RGH-188
Number of Participants With Adverse Event and Adverse Drug Reaction
Time frame: Up to 7 weeks
Maximum Plasma Concentration of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
Time frame: Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.
Time to Maximum Plasma Concentration of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
Time frame: Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.
Area Under the Plasma Concentration-Time Curve From Time Zero to Last of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
Time frame: Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 14 (Last Observation Carried Forward; LOCF)
PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.
Time frame: at baseline, and on Day 14 or a last observation carried forward (LOCF)
Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Day 14 (Last Observation Carried Forward; LOCF)
CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).
Time frame: at baseline, and on Day 14 or a last observation carried forward (LOCF)
The Clinical Global Impression-Improvement (CGI-I) Score at Day 14 (Last Observation Carried Forward; LOCF)
CGI-I is a 7-point scale to assess the global improvement of the participant's illness relative to baseline. CGI-I scores range from 1 (very much improved) to 7 (very much worse).
Time frame: on Day 14 or a last observation carried forward (LOCF)
| Milestone | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| Started | 12 | 10 | 12 |
| Completed | 9 | 9 | 9 |
| Not completed | 3 | 1 | 3 |
| Withdrew: Adverse event | 2 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
| Participants | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| Number of Participants With Adverse event | 9 | 9 | 11 |
| Number of Participants With Adverse drug Reaction | 5 | 6 | 10 |
| ng/mL | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| Unchanged MP-214 | 9.19 ± 3.47 | 19.43 ± 4.80 | 36.39 ± 8.53 |
| M7 (desmethyl cariprazine) | 3.14 ± 1.26 | 5.83 ± 1.87 | 11.37 ± 3.00 |
| M6 (didesmethyl cariprazine) | 13.79 ± 5.74 | 28.08 ± 14.52 | 54.99 ± 14.97 |
| hour | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| Unchanged MP-214 | 3.71 ± 0.99 | 3.48 ± 1.11 | 3.22 ± 0.45 |
| M7 (desmethyl cariprazine) | 5.25 ± 1.99 | 5.10 ± 1.94 | 4.36 ± 1.80 |
| M6 (didesmethyl cariprazine) | 4.79 ± 2.23 | 5.37 ± 2.14 | 5.22 ± 2.08 |
| ng*hr/mL | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| Unchanged MP-214 | 298.36 ± 128.04 | 522.38 ± 194.61 | 1017.96 ± 419.24 |
| M7 (desmethyl cariprazine) | 135.25 ± 64.80 | 232.38 ± 113.31 | 437.64 ± 131.76 |
| M6 (didesmethyl cariprazine) | 1884.24 ± 785.73 | 3397.12 ± 2395.44 | 5950.73 ± 1928.05 |
PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.
| units on a scale | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 14 (Last Observation Carried Forward; LOCF) | -0.2 ± 12.8 | -0.6 ± 15.6 | -3.9 ± 10.8 |
CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).
| units on a scale | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Day 14 (Last Observation Carried Forward; LOCF) | 0.3 ± 0.8 | -0.1 ± 0.9 | -0.1 ± 0.7 |
CGI-I is a 7-point scale to assess the global improvement of the participant's illness relative to baseline. CGI-I scores range from 1 (very much improved) to 7 (very much worse).
| units on a scale | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| The Clinical Global Impression-Improvement (CGI-I) Score at Day 14 (Last Observation Carried Forward; LOCF) | 4.1 ± 1.3 | 3.7 ± 1.2 | 3.8 ± 1.1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cariprazine 3 mg | — | 3/12 (25%) | 9/12 (75%) |
| Cariprazine 6 mg | — | 1/10 (10%) | 9/10 (90%) |
| Cariprazine 12.5 mg | — | 2/12 (16.7%) | 11/12 (91.7%) |
| Event | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 2/12 | 1/10 | 1/12 |
| Blood creatine phosphokinase increasedInvestigations | 0/12 | 1/10 | 0/12 |
| Tibia fractureInjury, poisoning and procedural complications | 1/12 | 0/10 | 0/12 |
| Neuroleptic malignant syndromeNervous system disorders | 0/12 | 0/10 | 1/12 |
| Event | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg |
|---|---|---|---|
| InsomniaPsychiatric disorders | 4/12 | 3/10 | 1/12 |
| NasopharyngitisInfections and infestations | 2/12 | 3/10 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 2/12 | 1/10 | 3/12 |
| Alanine aminotransferase increasedInvestigations | 1/12 | 0/10 | 3/12 |
| Blood creatine phosphokinase increasedInvestigations | 1/12 | 1/10 | 3/12 |
| White blood cell count increasedInvestigations | 0/12 | 0/10 | 3/12 |
| AkathisiaNervous system disorders | 1/12 | 1/10 | 3/12 |
| ToothacheGastrointestinal disorders | 0/12 | 2/10 | 0/12 |
| NauseaGastrointestinal disorders | 2/12 | 1/10 | 0/12 |
| PyrexiaGeneral disorders | 0/12 | 0/10 | 2/12 |
| Age, Customized(Participants) | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg | Total |
|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 |
| >=18 and =<30 years | 2 | 2 | 2 | 6 |
| >=31 and =<40 years | 2 | 4 | 3 | 9 |
| >=41 and =<55 years | 6 | 3 | 5 | 14 |
| >55 years | 2 | 1 | 2 | 5 |
| Sex: Female, Male(Participants) | Cariprazine 3 mg | Cariprazine 6 mg | Cariprazine 12.5 mg | Total |
|---|---|---|---|---|
| Female | 6 | 4 | 4 | 14 |
| Male | 6 | 6 | 8 | 20 |
The record gives a start of Apr 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2021, 11 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine